Investors eye Q2 results from Dr. Reddy’s, SBI Life, and SBI Cards

Investors awaited second-quarter earnings from Dr. Reddy’s Laboratories, SBI Life Insurance, and SBI Cards scheduled for release later today. Analysts forecast a 7–10% year-on-year revenue increase for Dr. Reddy’s, driven by strong North American generics performance. SBI Cards’ profit is expected to rise 18% sequentially to ₹606 crore on higher spending volumes, while SBI Life could post steady premium growth. The results will influence near-term sectoral sentiment and guide index positioning ahead of next week’s monthly derivatives expiry.